When every priority feels urgent, the problem isn't a lack of opportunity. It's knowing which decision will actually move the business forward.

There's a particular kind of pressure that comes with leading a growing MedTech company.

The pipeline needs attention. The next conference is approaching. Marketing has a campaign ready. Sales wants better enablement. The board is asking about commercial progress. There's a new market opportunity worth exploring, and the product team has another milestone on the horizon.

Every conversation ends with another thing to do.

And somewhere in the middle of all that activity, a question gets lost.

What should we actually do next?

Not what could we do. Not what would be useful. Not what has been sitting on the roadmap for six months.

What is the one decision or action that would create the greatest forward movement for the business right now?

It's a deceptively difficult question. And for many MedTech companies, the inability to answer it clearly is one of the most expensive problems they're carrying.

The Activity Trap

Most executive teams don't have an activity problem.

They have more ideas, initiatives, and potential opportunities than they have time or resources to pursue. The challenge is deciding which ones deserve attention and which ones are quietly consuming capacity without creating meaningful progress.

This is where activity starts to masquerade as momentum.

A marketing team publishes consistently. Sales attends every relevant event. The leadership team holds regular planning meetings. New initiatives are launched, and existing ones are reviewed.

The business is busy.

But busy and moving forward are not the same thing.

A full calendar doesn't tell you whether the right market is being targeted. A growing content library doesn't tell you whether the commercial story is resonating. More sales conversations don't necessarily mean the pipeline is becoming healthier.

The distinction matters because activity is easy to measure. Progress requires a much harder question: What has actually changed as a result of the work?

When that question isn't being asked, companies can spend entire quarters executing against priorities that were never the most important ones to begin with.

Why Everything Starts to Feel Urgent

In MedTech, the pressure to act is understandable.

There are regulatory milestones to capitalize on, clinical evidence to communicate, commercial partnerships to develop, and market opportunities that won't remain open indefinitely.

The stakes are real. So is the temptation to pursue everything at once.

But when every opportunity is treated as a priority, prioritization stops functioning.

The result is usually a collection of competing initiatives, each with a reasonable argument for why it matters. Marketing is working toward one objective. Sales is responding to another. Leadership is trying to keep everything moving while making decisions across multiple functions.

Nobody is necessarily doing the wrong thing.

The problem is that the business hasn't made a clear enough decision about what matters most.

And without that decision, resources get distributed across too many fronts. Teams lose the ability to build momentum behind any single initiative. Progress becomes fragmented, and the executive team spends more time managing competing demands than directing the business.

The answer isn't always to work harder or add more resources.

Sometimes it's to stop doing things that don't need to happen yet.

The Cost of Getting the Sequence Wrong

There's an important distinction between doing the right things and doing them in the right order.

A company might invest in a new marketing campaign when the underlying positioning is still unclear. It might expand its sales team before establishing a repeatable commercial process. It might invest in additional channels before understanding why its existing ones aren't converting.

Each decision can appear reasonable in isolation.

But if the underlying constraint hasn't been addressed, the investment often produces less than it should.

Consider a MedTech company experiencing slow pipeline progression.

The immediate response might be to generate more leads, increase campaign activity, or expand the sales effort.

But what if the real issue is that buyers don't understand the commercial value of the technology? What if the sales team is struggling to articulate the outcome because the messaging was built around product features rather than buyer priorities?

More leads won't resolve that problem.

They'll simply introduce more people to a story that isn't working.

This is why diagnosis has to precede action.

The most visible problem isn't always the most important one. And the action that feels most productive isn't necessarily the action that will create the greatest return.

The sequence matters.

The Question Behind the Question

When an executive team asks, "What should we do next?" the answer shouldn't begin with a list of initiatives.

It should begin with a better understanding of the business.

• Where is progress actually getting stuck?

• What is preventing the company from achieving the outcome it wants?

• Which assumptions are driving current decisions, and have they been tested?

• What is the business already doing that could work better with a clearer direction?

These questions shift the conversation away from activity and toward the constraint that is limiting progress.

In our work with MedTech companies, we often find that the issue sits further upstream than the team initially expects.

The perceived problem might be marketing performance, but the underlying issue is positioning. It might appear to be a sales problem, but the commercial narrative isn't giving buyers a compelling reason to act. It might look like a resource gap, when the real need is a clearer decision about where those resources should be deployed.

Until the underlying constraint is identified, the business risks investing in solutions that address the symptoms rather than the cause.

That is an expensive way to learn.

Prioritization Is a Leadership Decision

There's a reason prioritization can't simply be delegated to a project management tool or resolved through another planning meeting.

Choosing what matters most requires an understanding of the commercial strategy, the market, the available resources, and the consequences of getting the decision wrong.

It requires someone who can see across the business rather than within a single function.

For CEOs and senior executives, this is one of the most important responsibilities of leadership: creating the conditions for the organization to focus.

That means being willing to make decisions that aren't always comfortable.

To pause an initiative that has already consumed significant investment. To delay an opportunity that looks attractive but doesn't support the immediate commercial objective. To resist the pressure to add another channel, campaign, or workstream simply because it is available.

And, perhaps most importantly, to give the team a clear answer when they ask what deserves their attention.

A good priority decision doesn't just tell people what to do.

It tells them what they can stop worrying about.

That clarity has a compounding effect. Teams make decisions faster. Resources are deployed with greater intention. Communication becomes more consistent. The work that matters receives the attention it needs to produce an outcome.

From a List of Priorities to One Clear Move

This is where many strategic planning processes fall short.

They produce a roadmap containing everything the business would like to achieve, without making a meaningful distinction between what needs to happen now and what can wait.

The result is a plan that looks comprehensive but doesn't necessarily help anyone make a better decision on Monday morning.

A useful strategy should do the opposite.

It should reduce complexity. It should establish a clear relationship between the commercial objective, the constraint preventing progress, and the action most likely to address it. And it should be specific enough that the team knows what success looks like.

This doesn't mean ignoring the bigger picture. It means understanding how to move toward it in the right sequence.

Sometimes the highest-value move is a positioning decision. Sometimes it's a revised go-to-market approach, a stronger commercial narrative, or a clearer definition of the buyer.

The answer will be different for every company.

But the discipline is the same: identify the constraint, make the decision, and align the work around it.

One clear move, executed well, can create more progress than ten competing initiatives executed halfway.

The Value of Clarity

There's a reason the question "What should we do next?" is so difficult to answer.

It forces a company to confront the difference between what it wants to do and what the business actually needs.

That requires honest diagnosis, commercial perspective, and the willingness to make a choice.

But the alternative is more costly.

Another quarter of competing priorities. Another round of activity without clear commercial movement. Another set of decisions made in response to whatever feels most urgent that week.

For MedTech companies navigating a commercial inflection point, clarity isn't a luxury to pursue once everything else is under control.

It's what allows the business to move forward in the first place.

At Tribe, this is the work we do with CEOs and commercial leaders: identifying what's holding progress back, determining where attention will create the greatest value, and building the strategy that turns that decision into action.

Our One-Day Intensive is designed around exactly that process. One structured day to diagnose the commercial situation, identify the highest-leverage priority, and build a working strategy around it.

Because the goal isn't to leave with more things to do.

It's to leave knowing which thing matters most.

And sometimes, that's the decision that changes everything.

→ Explore Tribe's One-Day Intensive